Table 3.
The clinical studies of probiotics inhibiting colon cancer.
| Subjects | Probiotics | Food Sources of Probiotics | Treatments | Results | Ref. |
|---|---|---|---|---|---|
| 22 patients undergoing radical colectomy | Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis | NA | Subjects received capsules containing live microorganisms 3 times/day (total daily dose of 6 × 107 CFU). | Increased abundance and diversity of colonic mucosal microorganisms; decreased abundance of Fusobacterium and Peptostreptococcus. |
[123] |
| 60 patients who underwent resection of anterior sigmoid colon cancer | Bifidobacterium animalis subsp. lactis HY8002, Lacticaseibacillus casei HY2782, and Lactiplantibacillus plantarum HY7712 | NA | Subjects received probiotic powder treatment twice daily, for 4 weeks. | Improved control of flatulence; increased abundance of beneficial bacteria; and decreased abundance of harmful bacteria in the gut. |
[89] |
| 10 colon cancer patients and 20 healthy subjects | Lactobacillus gasseri OLL2716: LG21 | NA | Subjects administered probiotics daily, for 12 weeks. | Increased levels of Lactobacillus and decreased total Clostridium perfringens in the intestines; increased short-chain fatty acid isobutyrate in the feces; decreased pH; and decreased synthesis of spoilage products; increased NK cell activity. |
[91] |
| 38 men aged 24-55 | Lacticaseibacillus rhamnosus LC705 and Propionibacterium freudenreichii ssp. shermanii JS | NA | Subjects consumed 2 capsules containing live microorganisms (2 × 1010 CFU per strain) per day, for 4 weeks. | Increased levels of Lactobacillus and Propionibacterium in the intestinal tract; decreased β-glucosidase and urease activity. |
[94] |
| 68 patients with treated colon cancer | Lacticaseibacillus rhamnosus R0011 and Lactobacillus acidophilus R0052 | NA | Subjects were treated with probiotics (2 × 109 CFU) daily, for 12 weeks. | Improved bowel symptoms and quality of life. | [11] |
| 33 patients who underwent colectomy | Saccharomyces boulardii | NA | Subjects received preoperative probiotic oral therapy for at least 7 days. | Downregulation of mucosal IL-1β, IL-10, and IL-23A levels | [86] |
| 60 patients who underwent radical colorectal resection | Bifid triple viable probiotics | NA | Subjects received oral probiotic treatment 3 days before surgery. | Reduced serum endotoxin, D-lactic acid, and IL-6 levels; elevated IgG and IgA levels; reduced incidence of postoperative infectious complications. |
[85] |